Skip to Content

Zeposia Approval History

FDA Approved: Yes (First approved March 25, 2020)
Brand name: Zeposia
Generic name: ozanimod
Dosage form: Capsules
Company: Bristol-Myers Squibb Company
Treatment for: Multiple Sclerosis

Zeposia (ozanimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS).

Development History and FDA Approval Process for Zeposia

DateArticle
Mar 26, 2020Approval FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis
Jun  6, 2019US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
Mar 25, 2019Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
Feb 27, 2018Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide